| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8824664 | Médecine Nucléaire | 2016 | 4 Pages |
Abstract
In the treatment of unresectable liver metastases of colorectal cancer, radioembolization with SIR-Spheres confirms its place in the treatment of refractory disease with a gain in terms of response, progression-free survival, and also overall survival. In combination with first-line systemic standard chemotherapy (FOLFOX6m ± bevacizumab), the results of SIRFLOX study show an improvement in hepatic control (objective response rate and liver progression-free survival) without gain in progression-free survival at any site.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
J. Roux, L. Djaïleb, M.-D. Desruet, C. Gallazzini-Crepin, J.-P. Vuillez,